Regenicin Signs Supplier Agreement with Pure Med F
Post# of 99
Provide Closed Herd Collagen for the Manufacturing of NovaDerm®
November 17, 2016 - Regenicin, Inc. (OTC Bulletin Board: RGIN), a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, today announced that they have signed a supplier agreement with Pure Med Farma, LLC (PMF) to provide closed herd collagen for the production of its proprietary collagen scaffolds for the manufacturing of NovaDerm®. PMF is a related1 biotechnology company dedicated to bringing safe Animal Source Materials (ASMs) and Xenotransplantation materials to the global healthcare market using proprietary closed herd technology and biosecurity practices.
The agreement with PMF states Regenicin will receive priority pricing and guaranteed inventory availability. This is a key milestone, as guidance documents from the U.S. Food and Drug Administration (FDA) clearly state that any product requesting approval to enter clinical trials will be denied until the applicant presents evidence that components derived from animal sources were obtained from closed herds.2
According to Randall McCoy, Chief Executive Officer of Regenicin, “Regenicin will only use bovine closed herd collagen to produce NovaDerm. Using collagen that comes from a bovine closed herd provides a significant breakthrough in safety, as closed herd quality systems are designed to minimize exposure to pathogens which could be transferred to humans when using animal components for healthcare.”.According to Randall McCoy, Chief Executive Officer of Regenicin, “Regenicin will only use bovine closed herd collagen to produce NovaDerm. Using collagen that comes from a bovine closed herd provides a significant breakthrough in safety, as closed herd quality systems are designed to minimize exposure to pathogens which could be transferred to humans when using animal components for healthcare.”